<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667443</url>
  </required_header>
  <id_info>
    <org_study_id>MILA</org_study_id>
    <nct_id>NCT03667443</nct_id>
  </id_info>
  <brief_title>Myo-inositol Plus Alpha-lactalbumin in PCOS Myo-inositol-resistant Patients</brief_title>
  <official_title>The Effects of Myo-inositol Plus Alpha-lactalbumin in Ovulation Induction of PCOS Myo-inositol-resistant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lo.Li.Pharma s.r.l</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lo.Li.Pharma s.r.l</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's aim is to evaluate if the combination of myo-inositol and
      alpha-lactalbumin can overcome the resistance to myo-inositol in PCOS patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators expect about 30% of the PCOS patients enrolled to be
      resistant to Myo-inositol treatment for ovulation induction, probably due to the presence of
      malabsorption caused by gut dysbiosis. The most recent evidence proposes dysbiosis and
      related chronic low-grade inflammation as the new DOGMA behind PCOS pathogenesis. In this
      regard, the recent findings on alpha-lactalbumin reports its effect in improving the
      absorption of different nutrients including myo-inositol as well as a crucial factor for
      reducing inflammation. Furthermore, this whey protein is well known for its effect as trophic
      agent for gastrointestinal flora in infants. For all these reasons, the investigators expect
      that the treatment with Inofolic HP (Myo-inositol and alpha-lactalbumin) will get an efficacy
      20-25% higher than the treatment with inofolic.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ovulation induction</measure>
    <time_frame>after three months of treatment</time_frame>
    <description>Ovulation indaction will by evaluated through ultrasound sonography</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>PCOS</condition>
  <condition>Myo-inositol-resistance</condition>
  <arm_group>
    <arm_group_label>Myo-inositol plus folic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Myo-inositol + folic a. + α-lactalbumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol + folic a. + α-lactalbumin</intervention_name>
    <description>3 months of treatment</description>
    <arm_group_label>Myo-inositol + folic a. + α-lactalbumin</arm_group_label>
    <other_name>Inofolic HP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol + folic a.</intervention_name>
    <description>3 months of treatment</description>
    <arm_group_label>Myo-inositol plus folic</arm_group_label>
    <other_name>Inofolic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  POCS women diagnosed using the Rotterdam Criteria

        Exclusion Criteria:

          -  Amenorrhea (3 months)

          -  Other conditions causing ovulatory disorders and/or androgens hyper production such
             as: hyperprolactinemia, hypothyroidism, adrenal hyperplasia and Cushing syndrome

          -  Hormonal and/or pharmacological treatments in the previous 3 months that could
             interfere with ovulation

          -  Drastic changes in diet

          -  Treatment with product containing Myo-inositol in the previous 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>September 13, 2018</last_update_submitted>
  <last_update_submitted_qc>September 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myo-inositol</keyword>
  <keyword>alpha-lactalbumin</keyword>
  <keyword>polycystic ovary syndrome</keyword>
  <keyword>anovulation</keyword>
  <keyword>infertility</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

